Acute Aortic DissectionNCT06492980
A Triple-branched Stent Graft for Aute Debakey Type I Dissection Surgery
A study testing triple-branched stent graft in people with Acute Aortic Dissection, run by Fujian Medical University at 1 site in China.
Trial summary
Prospective, multicenter, randomized controlled clinical trial plan to evaluate the effectiveness and safety of intraoperative stent system in the treatment of acute type I aortic dissection Read more about this study
- Who is it for?
- Ages 20 to 65 years
- Conditions the study is for
- Acute Aortic Dissection
- What is being tested?
- triple-branched stent graft
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteChina
- Study dates
- 27 Oct 2023to 10 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with acute type I aortic dissection who need arch repair;
- Aged ≥20 years and ≤65 years;
- Acute phase, with onset within 14 days before surgery;
- Subjects who can understand the purpose of the trial, voluntarily participate and sign the informed consent form, and are willing to accept follow-up.
Who cannot join
- The presence of anatomical variations, such as aortic arch malformation, aortic coarctation; common origin of the innominate artery and the left common carotid artery, aberrant right subclavian artery, abnormal origin of the left conical artery, stenosis or distortion of the branch arteries; and the diameter of the aortic arch and branch artery diameters do not match the specifications of the test device;
- Dissection is secondary to a history of aortic treatment, Marfan syndrome, etc.
- Aortic lesions and branch artery lesions caused by acute type I aortic dissection, including aortic pre-rupture, branch artery rupture, branch artery occlusion, and severe ischemic complications caused by poor organ perfusion, such as myocardial ischemia, stroke (ischemic brain injury), paraplegia (spinal artery ischemia), mesenteric artery ischemia, renal artery dysplasia, etc.
- Severe infectious lesions that are not controlled;
- Patients who need to receive other concomitant treatments, such as severe hypertension, chronic obstructive pulmonary disease, coronary heart disease, chronic kidney disease and other serious underlying lesions that require long-term treatment;
- Patients with other life-threatening lesions, such as advanced malignant tumors, and whose expected survival time is less than one year;
- Patients with other lesions in the heart and aorta (patients with other heart diseases that require concurrent heart surgery, such as coronary heart disease, mitral valve disease, tricuspid valve disease, etc.), who are not suitable for stent interventional treatment, such as peripheral vascular disease and blood disease;
- Subjects who have participated in other drug or device clinical trials and have not reached the primary study endpoint; and pregnant women.
Trial locations and contacts
1 site in 1 country.
Xiao-fu Dai, M.D Ph.D contact
China1 site, 1 recruiting
- Recruiting
Department of Cardiovascular Surgery
Fuzhou, Fujian, 350001
Liang-Wan Chen, M.D, Ph.D, 86 13358255333, daixiaofu719@hotmail.com
E Lin, M.D, 86 13365912195, 1470054258@qq.com
About this study
Official title: Safety and Effectiveness of a Triple-branched Stent Graft for Arch Repair During Open Aute Debakey Type I Dissection Surgery - a Randomized Controlled Multicenter Clinical Trial
Prospective, multicenter, randomized controlled clinical trial plan to evaluate the effectiveness and safety of intraoperative stent system in the treatment of acute type I aortic dissection
Read the detailed description
Acute aortic dissection is a local rupture in the aortic intima. Blood flows into the middle layer from the rupture, causing the middle layer of the aortic wall to tear along the long axis, tearing the complete aortic wall into the dissected intima (intima + part of the middle layer) and the dissected outer wall (part of the middle layer + outer layer), and forming a true lumen (the original aortic lumen) and a false lumen (the cavity between the dissected intima and the dissected outer wall). The torn dissected outer wall bears the pressure of the entire aorta, which can easily cause aortic rupture. The clinical characteristics of this disease are acute onset and rapid progression, making it one of the most dangerous and fatal cardiovascular diseases. Acute type I aortic dissection involves the ascending aorta, aortic arch and the entire aorta, and is the most dangerous type of acute aortic dissection. At present, surgery is the only treatment for acute type I aortic dissection.
Since the most common rupture site of acute aortic dissection is in the ascending aorta, clinical trials have shown that simple ascending aortic replacement can effectively save the lives of most patients with acute type I aortic dissection, and this operation is simple and suitable for emergency rescue of such critically ill patients. Therefore, simple ascending aortic replacement has become a classic emergency surgical method for acute type I aortic dissection.
However, most patients with acute type I aortic dissection after simple ascending aortic replacement have residual false lumens in the aortic arch and its distal aorta (i.e., dissection lesions still exist). The expansion and rupture of these residual false lumens are the most important factors affecting the long-term efficacy after surgery.
During the operation, reconstruction of the aortic arch as much as possible, elimination of the intimal rupture of the arch and the proximal descending aorta, expansion of the true lumen, and promotion of thrombosis in the false lumen are the fundamental ways to improve the long-term effect after surgery. Therefore, for patients with a high probability of residual false lumen expansion and rupture, such as young patients, patients with a long postoperative survival time, and patients with multiple ruptures in the aortic arch, most scholars currently advocate that the aortic arch should be reconstructed at the same time as the ascending aorta replacement, and the four-branch artificial blood vessel is often used to replace the aortic arch, and the descending aorta fixed elephant trunk technique (Frozen Elephant Trunk Technique) is an effective method for the treatment of acute aortic dissection developed in recent years. It can effectively close the aortic intimal rupture, promote thrombosis in the false lumen, and expand the true lumen. In order to simplify the reconstruction of the aortic arch in acute type I aortic dissection, we designed an integrated three-branch covered stent system (referred to as the intraoperative stent system), which is implanted under direct vision during surgery to repair the aortic arch, that is, the three-branch covered stent is sent into the arch, the root of the branch artery and the descending part of the arch under deep hypothermic circulatory arrest to cover the rupture of the dissection in the arch, the root of the branch artery and the descending part of the arch, and the proximal end of the stent and the distal incision of the ascending aorta are directly anastomosed with the artificial blood vessel replacing the ascending aorta. This avoids the anastomosis of the three branches of the aortic arch, reduces the difficulty of surgery, and shortens the time of cerebral ischemia and lower body ischemia.
This clinical trial adopts a prospective, multicenter, randomized controlled method, with the marketed product descending aortic elephant trunk stent implantation (Frozen Elephant Trunk Technique) as a control, and evaluates the effectiveness and safety of the intraoperative stent system as a test device in the treatment of acute type I aortic dissection through a standardized experimental design.
This experimental device is an upgraded product of Beijing Yuhengjia Technology Co., Ltd.'s existing products. It was developed by Beijing Yuhengjia Technology Co., Ltd. and has transferred a full set of technical documents to Yuhengjia (Xiamen) Technology Co., Ltd.
Beijing Yuhengjia Technology Co., Ltd. uses the same materials and the same process to produce similar products "endovascular covered stent" for the treatment of thoracic descending aorta and abdominal aorta lesions. It has been approved by the National Medical Products Administration, obtained a product registration certificate, and used in clinical treatment, achieving the expected treatment purpose.
- Conditions
- Acute Aortic Dissection
- Being tested
- triple-branched stent graft
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
triple-branched stent graftProcedure or surgery
a triple-branched stent graft for aortic arch repairement during surgery
| Study group | Role | What they receive |
|---|---|---|
| Triple-branched stent graft group | Experimental | The device in this clinical trial implanted covered stents in the aortic arch, three branches, and descending thoracic aorta, replacing surgical anastomosis with interventional treatment. Receives: Procedure: triple-branched stent graft |
| Aortic arch replacement with frozen elephant trunk | Active comparator | This surgical method is ascending aorta + arch replacement + elephant trunk stent , that is, artificial blood vessels are used to replace the ascending aorta and aortic arch, arch anastomosis or three-branch blood vessel anastomosis is performed in the aortic arch, and a covered stent is placed in the descending thoracic aorta (Frozen Elephant Trunk Technique). Receives: Procedure: triple-branched stent graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality within 30days post-operation
Mortality within 30days post-operation
Measured: 30 days
Secondary outcomes (3)
Aortic dissection-related death occurred within 12 months after surgery
Aortic dissection-related death occurred within 12 months after surgery
Measured: 12 month
Thrombosis of the false lumen of the arch and proximal descending aorta
Thrombosis of the false lumen of the arch and proximal descending aorta
Measured: 12 month
Technical success
Successful insertion, successful positioning, and patency of the lumen were used as indicators
Measured: 12 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2024
- Study start27 Oct 2023
- Primary completion10 Oct 2024 (estimated)
- Study completion10 Oct 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Aortic DissectionStudies of the same condition, open and under way.
- More trials run by Fujian Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fujian Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Liang-Wan Chen MD, Fujian Medical University
- Investigators
- Liang-wan Chen, M.D Ph.D, Study chair, Fujian Medical University Union Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06492980
- Sponsor's protocol ID
- A202101
- Status last verified
- Jul 2024
- First submitted
- 8 Nov 2023
- Last updated
- 9 Jul 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Safety and Effectiveness of a Triple-branched Stent Graft for Arch Repair During Open Aute Debakey Type I Dissection Surgery - a Randomized Controlled Multicenter Clinical Trial
- ClinicalTrials.gov ID
- NCT06492980
- Acronym / sponsor ID
- A202101
- Conditions
- Acute Aortic Dissection
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Fujian Medical UniversityUniversity, hospital or other
- Study start
- 27 Oct 2023 (actual)
- Primary completion
- 10 Oct 2024 (estimated)
- Study completion
- 10 Oct 2025 (estimated)
- First posted
- 9 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective, multicenter, randomized controlled clinical trial plan to evaluate the effectiveness and safety of intraoperative stent system in the treatment of acute type I aortic dissection
Detailed description
Acute aortic dissection is a local rupture in the aortic intima. Blood flows into the middle layer from the rupture, causing the middle layer of the aortic wall to tear along the long axis, tearing the complete aortic wall into the dissected intima (intima + part of the middle layer) and the dissected outer wall (part of the middle layer + outer layer), and forming a true lumen (the original aortic lumen) and a false lumen (the cavity between the dissected intima and the dissected outer wall). The torn dissected outer wall bears the pressure of the entire aorta, which can easily cause aortic rupture. The clinical characteristics of this disease are acute onset and rapid progression, making it one of the most dangerous and fatal cardiovascular diseases. Acute type I aortic dissection involves the ascending aorta, aortic arch and the entire aorta, and is the most dangerous type of acute aortic dissection. At present, surgery is the only treatment for acute type I aortic dissection.
Since the most common rupture site of acute aortic dissection is in the ascending aorta, clinical trials have shown that simple ascending aortic replacement can effectively save the lives of most patients with acute type I aortic dissection, and this operation is simple and suitable for emergency rescue of such critically ill patients. Therefore, simple ascending aortic replacement has become a classic emergency surgical method for acute type I aortic dissection.
However, most patients with acute type I aortic dissection after simple ascending aortic replacement have residual false lumens in the aortic arch and its distal aorta (i.e., dissection lesions still exist). The expansion and rupture of these residual false lumens are the most important factors affecting the long-term efficacy after surgery.
During the operation, reconstruction of the aortic arch as much as possible, elimination of the intimal rupture of the arch and the proximal descending aorta, expansion of the true lumen, and promotion of thrombosis in the false lumen are the fundamental ways to improve the long-term effect after surgery. Therefore, for patients with a high probability of residual false lumen expansion and rupture, such as young patients, patients with a long postoperative survival time, and patients with multiple ruptures in the aortic arch, most scholars currently advocate that the aortic arch should be reconstructed at the same time as the ascending aorta replacement, and the four-branch artificial blood vessel is often used to replace the aortic arch, and the descending aorta fixed elephant trunk technique (Frozen Elephant Trunk Technique) is an effective method for the treatment of acute aortic dissection developed in recent years. It can effectively close the aortic intimal rupture, promote thrombosis in the false lumen, and expand the true lumen. In order to simplify the reconstruction of the aortic arch in acute type I aortic dissection, we designed an integrated three-branch covered stent system (referred to as the intraoperative stent system), which is implanted under direct vision during surgery to repair the aortic arch, that is, the three-branch covered stent is sent into the arch, the root of the branch artery and the descending part of the arch under deep hypothermic circulatory arrest to cover the rupture of the dissection in the arch, the root of the branch artery and the descending part of the arch, and the proximal end of the stent and the distal incision of the ascending aorta are directly anastomosed with the artificial blood vessel replacing the ascending aorta. This avoids the anastomosis of the three branches of the aortic arch, reduces the difficulty of surgery, and shortens the time of cerebral ischemia and lower body ischemia.
This clinical trial adopts a prospective, multicenter, randomized controlled method, with the marketed product descending aortic elephant trunk stent implantation (Frozen Elephant Trunk Technique) as a control, and evaluates the effectiveness and safety of the intraoperative stent system as a test device in the treatment of acute type I aortic dissection through a standardized experimental design.
This experimental device is an upgraded product of Beijing Yuhengjia Technology Co., Ltd.'s existing products. It was developed by Beijing Yuhengjia Technology Co., Ltd. and has transferred a full set of technical documents to Yuhengjia (Xiamen) Technology Co., Ltd.
Beijing Yuhengjia Technology Co., Ltd. uses the same materials and the same process to produce similar products "endovascular covered stent" for the treatment of thoracic descending aorta and abdominal aorta lesions. It has been approved by the National Medical Products Administration, obtained a product registration certificate, and used in clinical treatment, achieving the expected treatment purpose.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Triple-branched stent graft group | Experimental | Procedure: triple-branched stent graftThe device in this clinical trial implanted covered stents in the aortic arch, three branches, and descending thoracic aorta, replacing surgical anastomosis with interventional treatment. |
| Aortic arch replacement with frozen elephant trunk | Active comparator | Procedure: triple-branched stent graftThis surgical method is ascending aorta + arch replacement + elephant trunk stent , that is, artificial blood vessels are used to replace the ascending aorta and aortic arch, arch anastomosis or three-branch blood vessel anastomosis is performed in the aortic arch, and a covered stent is placed in the descending thoracic aorta (Frozen Elephant Trunk Technique). |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patients with acute type I aortic dissection who need arch repair;
- Aged ≥20 years and ≤65 years;
- Acute phase, with onset within 14 days before surgery;
- Subjects who can understand the purpose of the trial, voluntarily participate and sign the informed consent form, and are willing to accept follow-up.
Key exclusion criteria (8 listed)
- The presence of anatomical variations, such as aortic arch malformation, aortic coarctation; common origin of the innominate artery and the left common carotid artery, aberrant right subclavian artery, abnormal origin of the left conical artery, stenosis or distortion of the branch arteries; and the diameter of the aortic arch and branch artery diameters do not match the specifications of the test device;
- Dissection is secondary to a history of aortic treatment, Marfan syndrome, etc.
- Aortic lesions and branch artery lesions caused by acute type I aortic dissection, including aortic pre-rupture, branch artery rupture, branch artery occlusion, and severe ischemic complications caused by poor organ perfusion, such as myocardial ischemia, stroke (ischemic brain injury), paraplegia (spinal artery ischemia), mesenteric artery ischemia, renal artery dysplasia, etc.
- Severe infectious lesions that are not controlled;
- Patients who need to receive other concomitant treatments, such as severe hypertension, chronic obstructive pulmonary disease, coronary heart disease, chronic kidney disease and other serious underlying lesions that require long-term treatment;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| triple-branched stent grafta triple-branched stent graft for aortic arch repairement during surgery | Procedure or surgery | Aortic arch replacement with frozen elephant trunk, Triple-branched stent graft group |
Primary outcome
Mortality within 30days post-operation
Time frame: 30 days
Mortality within 30days post-operation
3 secondary outcomes
Aortic dissection-related death occurred within 12 months after surgery
Time frame: 12 month
Thrombosis of the false lumen of the arch and proximal descending aorta
Time frame: 12 month
Technical success
Time frame: 12 month
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Acute Aortic Dissection
Not yet recruitingObservational study
Clinical Health Outcomes Evaluation of Terumo Aortic Hybrid Devices
Aortic Aneurysm and Dissection
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
Aortic Arch Dissection, Aortic Arch Aneurysm
Active, not recruiting
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
Aortic Dissection
Enrolling by invitation
Endovascular Treatment of Thoracic Aortic Disease
Thoracic Aortic Aneurysms, Dissecting, Aneurysm
RecruitingObservational study
Potential Diagnostic Biomarkers for Aortic Dissection in the Emergency Department
Aortic Dissection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Xiao-fu Dai, M.D Ph.D contact
Liang-wan Chen, M.D Ph.D study chair
Fujian Medical University Union Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing triple-branched stent graft in people with Acute Aortic Dissection, run by Fujian Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Liang-wan Chen, M.D Ph.D (+8613358255333, chenliangwan@tom.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality within 30days post-operation (time frame: 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2024; AzTrials last refreshed its copy on 6 Nov 2026.